巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Immuron Limited

IMRN
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Immuron Limited - 延遲價格・最後更新於 26/01 6:58
最高位
3.780
最低位
3.660
開市價
--
前收市價
3.710
成交量(千)
1.56
成交額(百萬)
0.06
買入
3.650
賣出
3.770
每手股數
--
市值(百萬)
20.91
市盈率
--
息率
--
差價
--
52週高低
9.230 - 2.320
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Immuron Limited
證券代碼
IMRN.US
所屬板塊
Biotechnology
公司業務
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
發行量
5681164
公司總部
Chapman Street, Unit 10, 25-37, Blackburn North
公司網址
https://www.immuron.com.au
公司電話
+61 398245254

Immuron(IMRN.US)盤前漲超12% 旗下產品獲美國國防部資助

格隆匯·
Immuron(IMRN.US)盤前漲超12% 旗下產品獲美國國防部資助

Immuron(IMRN.US)盤前漲超12% 旗下產品獲美國國防部資助

格隆匯·
Immuron(IMRN.US)盤前漲超12% 旗下產品獲美國國防部資助

關於

Immuron Limited(IMRN.US)所屬的行業板塊為Biotechnology。
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
詳細公司背景可參考: https://www.immuron.com.au